SK Biopharm Q1 2026 Operating Profit Surges 249.7% to $62M
SK Biopharm reported Q1 2026 revenue of $157M and operating profit of $62M, up 57.8% and 249.7% year-over-year respectively. Growth was driven by expanding U.S. market penetration of Xcopri (cenobamate), its epilepsy treatment drug.
- SK Biopharm posted Q1 2026 revenue of $157M and operating profit of $62M, growing 57.8% and 249.7% YoY respectively
- Xcopri's U.S
- expansion fueled growth, but absent pipeline candidates and R&D spending remain headwinds
SK Biopharm reported Q1 2026 operating profit of $62M, a 249.7% surge year-over-year, according to a regulatory filing on May 7.
Financial Highlights
Both Q1 2026 revenue and operating profit significantly exceeded prior-year and prior-quarter results. Operating margin came in at 39.4%.
- Revenue: $157M, +57.8% YoY, +17.2% QoQ
- Operating Profit: $62M, +249.7% YoY, +94.0% QoQ
- Net Income: $71M, +423.5% YoY
- Net Income Attributable to Parent: $72M, +351.2% YoY
Market Reaction
The stock rallied following earnings, according to media reports. Press coverage identified U.S. market expansion of Xcopri (cenobamate), SK Biopharm's epilepsy therapeutic, as the key driver of accelerating results. However, analysts flagged concerns: Yonhap Infomax and pharmacist trade publications noted the absence of visible pipeline candidates and warned that expanded R&D spending could become a drag on future profitability. Hit News reported annual revenue has crossed the $480M threshold.
This article was auto-generated from regulatory filings and press reports for timely dissemination of key data. Please consult official company disclosures before making trading decisions.
326030Frequently Asked Questions
Why did SK Biopharm's earnings surge so dramatically?
According to media coverage, steady prescription growth for Xcopri (cenobamate), its epilepsy treatment currently marketed in the U.S., was the primary driver. Since SK Biopharm sells the drug directly in the U.S., revenue flows directly to bottom-line results.
Is a 39.4% operating margin considered high?
Operating margin represents the percentage of revenue retained as operating profit. At 39.4%, roughly $39 remains as operating profit per $100 in sales—a notably strong level for the pharma and biotech sector. Note this is preliminary and subject to audit adjustments.
Can SK Biopharm sustain this growth momentum?
The company did not provide forward guidance in this filing. However, analysts cautioned that the pipeline beyond Xcopri remains underdeveloped and that expanding R&D investment could pressure future margins. These factors warrant monitoring for longer-term earnings sustainability.
What is Xcopri and why is it driving results?
Xcopri (cenobamate) is an epilepsy treatment drug marketed in the U.S. Increasing prescriptions reflect growing market adoption and clinical demand, translating to higher revenues and profitability for SK Biopharm.
Wall Street's Defining Moments
See more
Smart Money Briefing
Weekly summaries of Wall Street guru moves and crypto whale activity.